Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders

Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations

(2022) Don Husereau et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Juvenile idiopathic arthritis

(2022) Alberto Martini et al.   Nature Reviews Disease Primers

Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review

(2021) Akira Yuasa et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Methods for the Economic Evaluation of Health Care Interventions for Priority Setting in the Health System: An Update From WHO CHOICE

(2021) Melanie Y. Bertram et al.   International Journal of Health Policy and Management

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

(2021) Matthew J. Page et al.   PLOS MEDICINE

Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA—a retrospective study of claims data from 2009 TO 2020

(2021) A. M. Orbai et al.   CLINICAL RHEUMATOLOGY

In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era

(2021) Werner Brouwer et al.   PHARMACOECONOMICS

A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy

(2020) Jiaqi Yao et al.   INFLAMMATORY BOWEL DISEASES

Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden

(2020) Hamed Khalili et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review

(2020) Akira Yuasa et al.   PHARMACOECONOMICS

Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation

(2019) Craig Mitton et al.   Applied Health Economics and Health Policy

Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment—A Systematic Literature Review

(2019) Batko et al.   International Journal of Environmental Research and Public Health

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT

(2018) Sarah Brown et al.   HEALTH TECHNOLOGY ASSESSMENT

Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review

(2018) Lucia Sara D’Angiolella et al.   PHARMACOECONOMICS

Sick Leave and Disability Pension in Prevalent Patients With Crohn’s Disease

(2018) Åsa H Everhov et al.   Journal of Crohns & Colitis

Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis

(2014) Wei Zhang et al.   PHARMACOECONOMICS

How to Estimate Productivity Costs in Economic Evaluations

(2014) Marieke Krol et al.   PHARMACOECONOMICS

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

(2013) Don Husereau et al.   BMC Medicine

Cost Per Responder Associated with Biologic Therapies for Crohn’s Disease, Psoriasis, and Rheumatoid Arthritis

(2012) Yifei Liu et al.   ADVANCES IN THERAPY

Do Productivity Costs Matter?

(2011) Marieke Krol et al.   PHARMACOECONOMICS

Quantifying the economic burden of productivity loss in rheumatoid arthritis

(2011) I. Filipovic et al.   RHEUMATOLOGY

Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

(2011) E. J. Soini et al.   JOURNAL OF MEDICAL ECONOMICS